Beacon Biosignals develops FDA-cleared wearable EEG technology combined with advanced AI to capture and analyze real-world neural data. Its platform provides clinicians and biopharma partners with objective measures of brain function intended to accelerate research, improve diagnostics and guide new treatments across neurology, psychiatry and sleep medicine. The company is led by CEO Jacob Donoghue and is based in Boston, MA. Beacon reported cumulative funding of over $132M following the Series B extension. The company plans to use the new proceeds to further scale at-home EEG deployments and expand its analytics capabilities to support diagnostics, clinical trials and precision medicine.

Total raised

$124M

Funding rounds

4

Latest round

Series B

Latest activity

Apr 2026